<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774302</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A03423-36</org_study_id>
    <nct_id>NCT04774302</nct_id>
  </id_info>
  <brief_title>Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With NAFLD</brief_title>
  <acronym>Cardio-NASH</acronym>
  <official_title>Study of Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Pasteur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to examine the link between Non-Alcoholic Fatty Liver Disease (NAFLD) and&#xD;
      cardiovascular diseases by studying the association between liver fibrosis degree and&#xD;
      cardiovascular risk factors. The study would clarify the value and the role of the Coronary&#xD;
      calcium score (CAC score) in the screening for coronary disease in this population at high&#xD;
      cardiovascular risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic Fibrosis and Cardiovascular Risk are evaluated by non invasive tests&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary calcium score</measure>
    <time_frame>At inclusion</time_frame>
    <description>Score in Agatston IU of coronary atherosclerosis risk;ranging from 0 to 100 : low risk; 100 to 400 : intermediate risk and &gt; 400 : high risk of coronary atherosclerosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Shear wave liver elastography</measure>
    <time_frame>At inclusion</time_frame>
    <description>Hepatic elasticity assessed in kPa : &lt;5 Kpa : normal; 5 to 8 kPa : low to moderate fibrosis ; &gt; 8 kPa : advanced fibrosis; &gt;15 kPa : cirrhosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ARFI Hepatic elasticity</measure>
    <time_frame>At inclusion</time_frame>
    <description>Hepatic elasticity assessed by Acoustic radiation force impulse (ARFI) (in kPa) Hepatic elasticity assessed in kPa : &lt;5 Kpa : normal; 5 to 8 kPa : low to moderate fibrosis ; &gt; 8 kPa : advanced fibrosis; &gt;15 kPa : cirrhosis .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk</measure>
    <time_frame>At inclusion</time_frame>
    <description>Systemic Coronary Risk Estimation (SCORE) ranging from &lt;1% very low risk to &gt;15% very high risk of cardiovascular mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary heart disease</measure>
    <time_frame>3 month</time_frame>
    <description>Diagnosis of coronary heart disease</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>NAFLD</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female evaluated in a dedicated hepatology day hospital, as part of a first&#xD;
        diagnostic workup or follow-up for already known NAFLD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NAFLD patients regardless of disease stage of severity (from simple steatosis to&#xD;
             cirrhosis)&#xD;
&#xD;
          -  Patient without known heart disease&#xD;
&#xD;
          -  Patient agreeing to participate and who has given his non opposition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Association with another cause of liver disease&#xD;
&#xD;
          -  Already known coronary artery disease&#xD;
&#xD;
          -  Pregnancy or breastfeeding in progress&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maeva GUILLAUME, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maeva GUILLAUME, MD</last_name>
    <phone>+33 5 62 21 16 02</phone>
    <email>mguillaume@clinique-pasteur.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31 076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maeva GUILLAUME, MD</last_name>
      <phone>+33 5 62 21 16 02</phone>
      <email>mguillaume@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Maeva GUILLAUME, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène BLASCO-PERRIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthieu GUIVARCH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Pasteur</investigator_affiliation>
    <investigator_full_name>Dr Maeva GUILLAUME</investigator_full_name>
    <investigator_title>Principal investigator, MD</investigator_title>
  </responsible_party>
  <keyword>CAC score</keyword>
  <keyword>Liver fibrosis</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>Metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

